admilparant (BMS-986278) / BMS - LARVOL DELTA

Baseline Characteristics of Patients in a Phase 3, Randomized, Placebo-Controlled Trial of Admilparant (BMS-986278), an Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Progressive Pulmonary Fibrosis (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Immunology • Pulmonary Disease • Respiratory Diseases

Admilparant normalizes the vascular niche: evidence from precision-cut lung slices (ERS 2026) - "Our findings demonstrate that admilparant acts as a modulator of the vascular niche. Given its clinical activity, these data highlight vascular normalization as a potent mechanism for slowing the progression of fibrotic lung disease, consistent with a therapeutic effect. Additional effects in epithelial and fibroblast cells suggest that admilparant targets multiple pathways across key cell types involved in fibrosis, providing a multicellular treatment for fibrotic lung disease."

Fibrosis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • HMGA2

A pharmacodynamic marker for admilparant: dose-dependent suppression of CA-125 in idiopathic pulmonary fibrosis (ERS 2026) - P2 | "These findings position CA-125 as a disease-relevant, dose-responsive biomarker of admilparant activity in patients with IPF, with early treatment-associated reductions by week 12 showing prognostic value for beneficial ppFVC outcomes at week 26 and potential utility for informing PK/PD modeling and advancing mechanistic understanding of treatment effects."

PK/PD data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Baseline characteristics of patients in the ALOFT-PPF phase 3, randomized, placebo-controlled trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 (LPA1) antagonist, in progressive pulmonary fibrosis (ERS 2026) - P3 | "ALOFT-PPF enrolled a diverse and representative population for the assessment of admilparant for the treatment of patients with PPF."

Clinical • P3 data • Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Process development for sustainable manufacturing of BMS-986278 (ACS-Fall 2026) - "In this presentation, we describe the strategy and key decisions that enabled the development of an improved third generation route to BMS 986278, a potent LPA1 antagonist. Emphasis is placed on route design considerations and the development, scale up, and on scale troubleshooting of selected key transformations that were critical to delivering a robust and sustainable manufacturing process."

LPA1-Induced EMT of Retinal Pigment Epithelial Cells Promotes Subretinal Fibrosis via USP1-Mediated Deubiquitination and Stabilization of ZEB1. (PubMed, Invest Ophthalmol Vis Sci) - "The antifibrotic effects and the safety of LPA1 inhibition by BMS-986278 were assessed in vivo...LPA1 promotes SRF by driving RPE EMT through USP1-mediated deubiquitination and stabilization of ZEB1. Targeting the LPA1/USP1/ZEB1 axis may provide a promising therapeutic strategy for nAMD-associated SRF."

Journal • Age-related Macular Degeneration • Fibrosis • Immunology • Macular Degeneration • Ophthalmology • Retinal Disorders • Targeted Protein Degradation • Wet Age-related Macular Degeneration • USP1 • ZEB1

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Completed

Trial completion

Admilparant: Data readout from P3 ALOFT-IPF trial (NCT06003426) for idiopathic pulmonary fibrosis in 2026 (Bristol-Myers Squibb) - Q2 2026 Results

P3 data • Idiopathic Pulmonary Fibrosis

Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant. (PubMed, Respir Res) - P2 | "Treatment with 60-mg admilparant improved circulating biomarkers associated with epithelial injury and fibrosis in IPF, and with inflammation, fibrosis, and collagen degradation in PPF. Proteomic analysis identified additional biomarkers associated with mitochondrial and metabolic pathways in IPF. These findings expand our understanding of potential mechanisms of LPA1 antagonism with admilparant and identify biomarkers that may help evaluate treatment response and disease activity."

Biomarker • Journal • P2 data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • ANGPTL3 • CD163 • CD31 • CHI3L1 • CKMT1A • IGFBP6 • KIM1 • MMP7 • MUC16 • PD-L2 • PECAM1 • POSTN • VCAM1

IM0271016: A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. (clinicaltrialsregister.eu) - P2/3 | N=154 | Not yet recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company

New P2/3 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Disease Mechanisms and Therapeutic Advances in Idiopathic and Progressive Pulmonary Fibrosis: From Approved Drugs to Emerging Strategies. (PubMed, J Clin Med) - "In particular, the shift from ineffective anti-inflammatory strategies to the success of nintedanib and pirfenidone in both IPF and non-IPF progressive diseases is discussed. Furthermore, recent advances from phase II and III clinical trials targeting specific molecular drivers of fibrosis and vascular remodeling are analyzed, with a focus on pathway-oriented therapies, including nerandomilast, admilparant, and inhaled treprostinil. Understanding this molecular crosstalk is essential for the development of new therapeutic strategy based on precision medicine and it may support a new era of combination approaches aimed at stabilizing disease and improving patient outcomes in both idiopathic and progressive pulmonary fibrosis."

Journal • Review • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis. (PubMed, Front Med (Lausanne)) - "The current standard-of-care agents, pirfenidone and nintedanib, merely slow disease progression and are burdened by significant toxicity...Analysis reveals that targeting broad-spectrum enzymes (e.g., autotaxin via ziritaxestat) or downstream effectors (e.g., Connective Tissue Growth Factor (CTGF) via pamrevlumab) has failed, likely due to mechanistic redundancy or insufficient target engagement. In contrast, highly specific, next-generation inhibitors targeting upstream signal initiation points such as the lysophosphatidic acid receptor 1 (LPAR1) (admilparant) and local αvβ6 integrin-mediated activation of transforming growth factor-beta (TGF-β) (bexotegrast) have yielded promising Phase 2 data, demonstrating a sophisticated translational learning loop. Furthermore, the geroscience approach targeting cellular senescence (dasatinib/quercetin) has introduced a controversial new paradigm, while the recent approval of nerandomilast (a phosphodiesterase 4B (PDE4B)..."

Journal • Review • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • CTGF • TGFB1

Admilparant: Data readout from P3 ALOFT-PPF trial (NCT06025578) for progressive pulmonary fibrosis in 2027 (Bristol-Myers Squibb) - Q1 2026 Results

P3 data • Idiopathic Pulmonary Fibrosis

Evolving management of SARD-ILD : Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases (PubMed, Z Rheumatol) - "Promising results from ongoing clinical studies provide new therapeutic perspectives for SARD-ILD and PPF and may significantly improve prognosis and disease burden in the future."

Journal • Review • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatology

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P3 | N=1255 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Oct 2026 ➔ Jun 2027

Trial completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis (clinicaltrials.gov) - P3 | N=2277 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

New P3 trial • Immunology • Pulmonary Disease • Respiratory Diseases

Assessment of Pharmacokinetic Interactions between Admilparant (BMS-986278) and Nintedanib or Pirfenidone (ATS 2026) - No abstract available

PK/PD data • Interstitial Lung Disease

Baseline Characteristics of Patients in the ALOFT-IPF Phase 3, Randomized, Placebo-Controlled Trial of Admilparant (BMS-986278), an Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Idiopathic Pulmonary Fibrosis (ATS 2026) - No abstract available

Clinical • P3 data • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Admilparant Reduces Mediators of Fibrosis in a Novel Patient-Derived Interstitial Lung Disease Tissue Culture System (ATS 2026) - No abstract available

Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (lpa1) Antagonists With Distinct Lung Occupancy Profiles and Vascular Effects (ATS 2026) - No abstract available

Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

New P1 trial

Admilparant: Data readout from P3 ALOFT-IPF trial (NCT06003426) for idiopathic pulmonary fibrosis in 2026 (Bristol-Myers Squibb) - Q4 2025 Results

P3 data • Idiopathic Pulmonary Fibrosis

A Study to Assess the Effect of Food on the Drug Levels of Admilparant (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Completed

Trial completion

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis (clinicaltrials.gov) - P3 | N=1092 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Pulmonary Disease • Respiratory Diseases